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The engrafted organ becomes a chimera as the recipient's leukocytes station 
themselves in the transplant. Remarkably, the recipient becomes chimeric 
as well, in a reverse migration involving immune cells from the graft. Interactions 
between donor and recipient cells are tolerogenic-a process with implications 
for the goal of graft acceptance with minimal immunosuppression. 
More than three decades have passed since clinical 
organ transplantation first emerged from investi-
gations that identified graft rejection as an immune 
reaction reversible by immunosuppressive drugs. 
Until recently, however, the very successes of trans-
plantation hid an odd truth: The successes are im-
munologicallyenigmatic and have become more so 
even as new drugs have broadened the therapeutic 
possibilities. Among current immunosuppres-
sants, deoxyspergualin appears to block early 
stages of lymphocyte activation by impeding anti-
gen presentation to resting helper T cells. Cy-
closporine and FK 506 (tacrolimus) affect later 
stages, disrupting T-cell internal signals and thus 
suppressing secretion of cytokines-notably, inter-
leukin-2. Rapamycin permits IL-2 secretion but 
blocks IL-2's actions. Antimetabolites, including 
azathioprine, cyclophosphamide, and methotrex-
ate, act even more distally, inhibiting immune-cell 
clonal proliferation. Despite these diverse and non-
specific mechanisms, the drugs all promote a 
donor/recipient immunologic balance. It is as if 
they encourage an unknown tolerogenic process. 
The nature of that process is beginning to be de-
fined. Almost from the outset of clinical organ 
transplantation, it was apparent that a successful 
graft becomes chimeric, adopting immune cells 
from the reCipient. It is now clear that the reCipient 
becomes chimeric too (Figure 1). Evidently, the 
donor and reCipient immune-cell populations in-
teract to foster graft acceptance. The crUCial im-
munologically active cells migrating from donor 
tissue to recipient target sites appear to be dendrit-
ic cells-a type of immune cell that is difficult to 
isolate and was until recently impossible to main-
tain in culture, and yet is the most potent of all cells 
that present antigens to T lymphocytes. Study of 
dendritic cells in animal allograft recipients sug-
gests the existence of tolerogenic mechanisms in 
which immature donor dendritic cells may act as 
"veto cells" to reprogram the recipient's immune 
surveillance. The findings raise the possibility of 
increasing the success of organ transplantation by 
various means, including perioperative donor-cell 
infusions. 
One-Way Paradigm 
Perhaps nothing has so impeded discovery of the 
donor/recipient immune interactions that follow 
organ transplantation as the divergences between 
the therapeutic traditions of bone marrow and 
solid organ grafting. Each has laid down its own 
concepts of the immunologic reqUirements for 
clinical success. A discussion ofthis misleading di-
chotomy is a good starting point for a survey of re-
cent developments and tl1eir clinical implications. 
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Figure 1. Two-way chimerism following organ transplanta-
tion is evidenced by immunostaining for specific HLA al-
leles in patients with a graft from a donor mismatched at 
that locus. Graft chimerism is shown in a biopsy specimen 
from a small-intestinal graft (left), obtained 54 days after the 
surgery. Red-colored staining for the recipient's HLA-Bw4 
shows that recipient cells have populated the graft's lamina 
propria. The blue-staining epithelium and endothelium are 
still of donor origin. Host chimerism is displayed in tissue 
from an inguinal lymph node of a kidney recipient (right) . 
Red-colored staining marks an even scattering of cells pos-
itive for the kidney donor's HLA-B7,40. The transplantation 
had been performed 29 years earlier. Two-way chimerism 
appears to characterize all successful allografts. 
Therapeutic bone marrow 
transplantation derived in the 
1960s from laboratory investi-
gations of Peter Medawar and 
colleagues in England, whose 
work provided a pioneering de-
scription of acquired immune 
tolerance. In initial experiments, 
spleen cells from adult mice 
were injected into immuno-
incompetent fetal or neonatal 
mice. The injected cells prolifer-
ated, essentially endowing each 
host with the donor's immune 
system. The host was thereby 
rendered incapable of recogniZ-
ing subsequent donor grafts as 
nonself. Further studies estab-
lished that irradiation of adult 
mice achieved the same end: Ab-
lation of hematolymphopoietic 
cells rendered the animals "new-
born," in the sense of being inca-
pable of rejecting engrafted bone 
marrow. 
It soon emerged, however, that 
an immunologically active graft 
could reject Its reCipient. The 
risk proved to be roughly pro-
portional to the extent of mis-
match between donor and reCip-
Ient histocompatibility antigens. 
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Hence, close matching would be 
needed. Eventually, a strategy 
for clinical bone marrow graft-
Ing emerged from the experi-
mental findings. In receiving 
bone marrow after cytoablative 
irradiation , the patient got a new 
immune system from the donor. 
But HLA matching between 
donor and reCipient was essen-
tial to prevent graft-versus-host 
disease. After successful engraft-
ment, maintenance immuno-
suppression was often not need-
ed-a circumstance reminiscent 
of the acquired tolerance identi-
fied in mice. 
For solid organ transplanta-
tion, the situation seemed qUite 
different. By 1968, when bone 
marrow grafting achieved its 
first clinical successes, thou-
sands of solid organ transplan-
tations, chiefly of kidneys, had 
been performed, using im-
munosuppression to prevent re-
jection and relying less on HLA 
matching. The number of renal 
transplantations had started to 
climb in mld-1962, when It be-
came clear that rejection of 
renal allografts by patients re-
celvlng baseline azathioprine 
therapy could be reversed by 
the addition of, or Intensifica-
tion of therapy with, the highly 
dose-maneuverable corticos-
teroid prednisone (Figure 2) . 
Agents that came Into use later 
as baseline therapy, Including 
cyclosporlne and tacrolimus, 
were more potent and reliable. 
Allotransplantation was ex-
panded to Include transplanta-
tion of liver, heart, lungs, pan-
creas, and intestine. Meanwhile, 
It was becoming evident that de-
spite lack of HLA matching, pa-
tients' need for maintenance im-
munosuppression often gradu-
ally declined. Indeed , in 
occasional patients such treat-
ment could eventually be dis-
continued. 
What precisely did immuno-
suppression achieve in reCipi-
ents of a solid organ transplant? 
The graft-versus-host disease 
seen after bone marrow trans-
plantation could be viewed as a 
unidirectional Immune reaction 
in which engrafted immune cells 
attack a defenseless host. By 
analogy, rejection of an engrafted 
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Figure 2. Typical use of immunosuppressive drugs to cir-
cumvent transplant rejection is shown by the postopera-
tive course of an early (1963) kidney allograft recipient. 
After more than two weeks of azathioprine therapy and 
good renal function, deterioration of creatinine clear-
ance and blood urea nitrogen level revealed the onset of 
rejection, which was reversed by addition of prednisone. 
The patient was weaned from the corticosteroid, and 
the azathioprine dosage was decreased to levels less 
than those that had earlier failed to forestall rejection. 
Subsequent graft function remained stable, despite a 
lack of HLA matching between donor and reCipient. 
solid organ could be viewed as a 
one-way process in which host 
immune cells destroy a defense-
less allograft (Figure 3). Im-
munosuppression would thus 
serve simply to stifle the host im-
mune system. However, there 
were hints of a more complex, 
accommodative process in or-
gan reCipients. 
Two-Way Paradigm 
An early clinical hint emerged 
in 1964 from studies of kid-
ney donors and reCipients by 
Charles Kirkpatrick and W E. C. 
Wilson, immunology fellows on 
the service of David Talmage 
at the University of Colorado. 
The investigators looked at kid-
ney transplantations from do-
nors with positive skin tests for 
tuberculin or other antigens to 
reCipients with negative skin 
tests. After surgery, 77% of the 
reCipients (47 of 61) showed 
positive tests, indicating that 
skin-test conversion had been 
acquired along with the organ. 
In the remainder, who still had 
negative skin tests, the trans-
plant had been rejected. The im-
plication-that functioning im-
mune cells had migrated from 
successful grafts into recipients' 
tissues-was generally deemed 
untenable, since the kidney was 
thought to be leukocyte-poor. 
Similar clues emerged in liver-
transplant reCipients, who were 
found to have acquired circulat-
ing donor-specific immunoglob-
ulin types. This, too, was gener-
ally discounted. 
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Figure 3. One-way paradigms of immunologic events in transplantation reflect 
early concepts of poor outcomes as the result of one-sided wars. In bone 
marrow transplantation (top), the host, pretreated with cytoablative irradia-
tion, was thought to have no residual immune system. Thus, in the absence of 
HLA matching, graft immune cells would prOliferate and mount an unan-
swered attack (graft-versus-host [GVH] disease). In organ transplantation 
(bottom), the graft (e.g., kidney) was thought to have no inherent immune sys-
tem. In the absence of pharmacologic immunosuppression, host cells would 
proliferate and attack (host-versus-graft [HVG] disease). 
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Meanwhile, it was becoming 
clear that immune cells could 
migrate from host to graft. The 
first hint came in 1969 from 
karyotyping studies in female re-
Cipients of livers from male ca-
davers. In the engrafted organ, 
hepatocytes and the endotheli-
um of the major blood vessels 
retained the donor male sex 
karyotype. But within 100 days 
of transplantation, the entire 
macrophage system, including 
Kupffer cells, had been replaced 
by female macrophages, as evi-
denced by the cells' Barr bodies. 
In 1991, it was found, first in 
rats and then in humans, that 
transplanted intestine becomes 
chimeric in much the same way. 
The bowel epithelium remains 
that of the donor, but lym-
phoreticular cells become those 
of the recipient. For the first 
time, it was proposed that graft 
chimerism might be common 
to all accepted grafts-a specu-
lation soon confirmed in stud-
ies of kidney. heart, and lung 
grafts. 
Until then, the assumption 
had been that an engrafted 
organ's lymphocytes were sim-
ply destroyed by the host. Ani-
mal experiments began to sug-
gest otherwise when work at the 
University of Pittsburgh showed 
that donor lymphocytes from 
small-bowel allografts in rats re-
ceiving tacrolimus used vascular 
routes to home in on widely dis-
tributed host lymphoid tissues. 
Although a graft-versus-host re-
action was identified, it was sus-
pected to be a peculiarity of the 
rat-strain combination being uti-
lized. 
Thus, in 1992, Pittsburgh in-
vestigators undertook to find 
systemiC chimerism (donor 
leukocytes inhabiting host tis-
sues) in human kidney and liver 
transplant reCipients. Those 
studied included some of the 
same patients whose skin tests 
had been investigated three 
decades earlier, who were now 
among the world's longest sur-
vivors of kidney grafts. 
The search for donor cells in 
such hosts was facilitated by 
new techniques of immuno-
staining or polymerase chain re-
action (PCR) analysis for identi-
fication of a Y chromosome-un-
equivocal evidence of systemic 
chimerization when found in 
cells of female recipients of or~ 
gans from male donors-or of 
HLA alleles characteristic of 
chromosome 6 of the donor but 
not the recipient. Five kidney re-
Cipients were studied 27 to 29 
years after transplantation. In 
one, all immunosuppressive 
treatment had been stopped 12 
years earlier; the others were 
still receiving azathioprine with 
or without prednisone. For four 
reCipients, the kidney donor was 
still available for immunologic 
studies, including HLA retyping. 
In each case. lymphocytes that 
resembled dendritic cells and 
had HLA types matching the 
donor but not the reCipient were 
identified in the recipient's skin 
and lymph nodes. In the fifth pa-
tient, a woman who had received 
one of her father's kidneys 29 
years earlier, cells with a Y chro-
mosome were identified in the 
skin. In all five. kidney biopsy 
showed that donor immune 
cells had been replaced by recip-
ientcells. 
Liver recipients had the same 
patterns. Of21O patients treated 
at either the University of Col-
orado or the University of Pitts-
burgh from 1963 to 1981. 44 
were still living in January 1992. 
Six had not taken baseline im-
munosuppressive drugs for five 
to 13 years, and five had suc-
cessfully stopped taking pred-
nisone. For most of the others. 
drug weaning had been started. 
The five drug-free patients, and 
an additional group randomly 
selected from those still taking 
immunosuppressants, consent-
ed to biopsy studies. In every 
one of 22 reCipients examined. 
donor cells could be identified 
in skin and lymph nodes by 
Y-chromosome testing, HLA typ-
ing. or both. 
These fmdings are paralleled 
by observations in children who 
have undergone liver transplan-
tation for type N glycogen stor-
age disease. a congenital enzyme 
deficiency leading to systemic 
accumulation of an insoluble 
amylopectin-like polysaccha-
ride. Patients who do not die 
from cirrhosis, which usually 
develops within a year or two 
after birth, remain at risk for 
lethal cardiomyopathy or neuro-
muscular syndromes. Remark-
ably. transplant recipients have 
shown amylopectin absorption 
in extrahepatic tissues. includ-
ing the heart. as long as six years 
after liver replacement. In two 
such patients. donor lympho-
cytes were found in the heart. 
apparently serving as enzyme 
carriers, as long as 91 months 
after surgery. 
Similar chimerization and 
metabolic benefit have followed 
liver transplantation in a child 
with the glucocerebrosidase de-
ficiency of type I Gaucher's dis-
ease. Such disorders had been 
thought to be correctable only by 
bone marrow transplantation. 
Evidently. any successful trans-
plantation procedure may re-
store metabolic function. More-
over, the number of allogeneic 
cells required appears to be sur-
prisingly small. 
Role of Dendritic Cells 
In essence, every organ trans-
plantation results in bidirection-
al traffic of immune cells. On the 
one hand. host cells migrate to 
the donated organ. On the other 
hand. immunologically active 
donor cells are assimilated into 
the host's vastly greater immune 
network (Figure 4). The traffic 
apparently leads to a mutual ac-
commodation. provided that the 
graft and host can survive the 
initial confrontation. 
A crucial issue is how small 
numbers of donor cells entering 
foreign territory can profoundly 
alter the activities of the host's 
immunologic army. Although 
donor cells have multiple lin-
eages. the most important type 
appears to be the antigen-pre-
senting dendritic leukocyte. de-
scribed in the 1970s by Ralph 
M. Steinman and Zanvil A. Cohn 
at Rockefeller University. First 
isolated from mouse lymphoid 
tissue during studies of accesso-
ry cells in immune responses. 
dendritic leukocytes have long 
fascinated researchers. Among 
bone marrow-derived leuko-
cytes. they are numerically 
small. yet they are distributed 
throughout the body. including 
the interstitium of organs such 
as the kidneys and heart. where 
immunologically active cells 
were once thought to be virtually 
absent. Unlike macrophages. 
they constitutively express high 
levels of major histocompatibili-
ty complex (MHC) class II 
molecules-which suggests spe-
cialization for antigen presenta-
tion. In fact. they are the most 
potent known cellular stimula-
tors of T-cell responses. both in 
vitro and in vivo. Dendritic cells 
had been impossible to culture 
until the recent discovery that 
gr an ulocyte -macrophage 
colony-stimulating factor (GM-
CSF) promotes propagation of 
dendritic-cell precursors. 
A series of experiments con-
ducted in Pittsburgh by Lina Lu 
and colleagues has probed the 
role of dendritiC cells in inducing 
tolerance to an engrafted organ. 
The investigators studied the 
transplanted liver. which ap-
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Figure 4. Two-way paradigms of bone marrow and solid 
organ grafting reflect the recognition that both a graft and 
its recipient become chimeric. In marrow transplantation 
(top), cytoablative pretreatment never completely destroys 
the host's immune system; in organ transplantation (bot-
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tom), the donated organ always has "passenger leuko-
cytes" (giving the host what amounts to a covert bone mar-
row graft). For the marrow recipient, the immune-cell traffic 
is predominantly graft-versus-host (GVH), whereas for the 
organ recipient, it is chiefly host-versus-graft (HVG). 
pears to be the graft for which 
tolerance is achieved most easi-
ly. Indeed, experimental liver al-
lotransplantation in mice-a 
technical tour de force achieved 
by Shiguang Qien and col-
leagues-usually requires no re-
Cipient immunosuppression. 
Additionally, a liver transplant 
gives the recipient mouse in-
creased receptivity to concur-
rent or subsequent transplants 
from the donor strain. In such 
ways, the liver demonstrates an 
inherent capacity to render the 
recipient more accepting of all 
donor tissues; this may reflect 
the organ's richness in immuno-
logically active cells, which in 
turn may reflect the liver's role 
as a fetal center of hematopoiesis. 
In initial experiments, non-
parenchymal cells from mouse 
liver were cultured in medium 
enriched with GM-CSF. About 
107 such cells were obtainable 
from each organ. After seven 
days, a subpopulation of some 
two million cells floating free 
in the medium expressed cell-
surface markers characteristic 
of dendritic cells. Macrophages 
and fibroblasts also proliferated 
but remained attached to the 
culture plate. Microscopic exam-
ination of the free-floating cells 
showed them to have the mor-
phology of dendritic cells, in-
cluding veil-like cytoplasmic ex-
tensions (Figure 5). The cells 
were avidly phagocytic but were 
poor stimulators of allogeneic T 
cells. In short, they resembled 
immunologically immature den-
dritic cells. They could not be in-
duced to mature. 
The impasse was broken by 
simulation of a hepatic microen-
vironment, created by transfer-
ring the cells to culture plates 
coated with type I collagen. This 
induced a hallmark of dendritic-
cell maturity, strong expression 
of class II antigen. The cells ex-
hibited a concomitant decrease 
------_._----_. __ .. _--_ .. 
in phagocytic activity and an in-
crease in their ability to stimu-
late T-cell proliferation. Injected 
into the footpad of mice , purified 
dendritic-cell precursors homed 
in on T-cell areas oflymph nodes 
and the spleen, where they too 
could be shown to augment ex-
pression of class II antigen. 
Next, liver transplantations 
were performed for a fully allo-
geneic (MHC class I-disparate 
and class II-disparate), but non-
rejecting, mouse-strain combi-
nation. Samples of the reCipi-
ent's bone marrow and spleen 
showed nidi of donor as well as 
recipient dendritic cells at vary-
ing stages of maturation, as 
identified by the techniques 
used in culture experiments. 
The proportions of immature 
and mature cells 150 days after 
transplantation were much the 
same as at two weeks. 
The possible significance of 
these immunologic oases for the 
induction of tolerance to a graft 
is suggested by recent experi-
ments of J. W. Streilein and col-
leagues at the University of 
Miami, and now at Harvard Uni-
versity, in which the anterior 
chamber of the eye, with its con-
stituent iris, ciliary body, and 
other tissues, has proved to be 
an immunologically privileged 
site, lined by immature dendrit-
ic cells. An antigenic peptide 
(bovine serum albumin) injected 
into the eye of a laboratory ani-
mal is taken up by these cells, 
which within a few hours pre-
sent the antigen to T cells in re-
gional lymph nodes and the 
spleen. When the animal is sys-
temically challenged with the 
same antigen 30 days later, the 
surprising consequence is an 
anergiC response instead of the 
expected hypersensitivity. 
Evidently, immature dendritic 
cells present antigen in an "ab-
normal" manner, which leads 
not to sensitization but to tolero-
genesis-a phenomenon that 
Streilein's group calls the anterior-
chamber-associated immune-
deviation complex. The implica-
tion is that immature dendritiC 
cells migrating from an engraft-
ed organ and immature, anti-
gen-bearing dendritiC cells mi-
grating from the anterior cham-
ber of the eye are fundamentally 
the same. 
Successful immunosuppres-
sive treatment of an organ-trans-
plant reCipient thus appears to 
promote an immunologic bal-
ance. The nonspecific effects of 
immunosuppressive drugs, in-
imical to cell proliferation, in-
deed suppress clonal expan-
Sion-notably, that of host cyto-
toxic T lymphocytes, which 
would otherwise mount a rejec-
tion response. At the same time, 
however, such drugs permit a 
process dependent on the move-
ment of donor cells from the 
graft to its reCipient. The mas-
sive cytokine release represent-
ing the host's naive response to 
the insult of transplantation 
seems conducive to such traffic, 
in that mediators such as cy-
tokines or conventional growth 
factors may promote cell pas-
sage from and into the graft. 
Immunosuppression enables 
graft and reCipient immune cells 
to meet, mingle, and react. with-
out leading to graft failure. The 
drugs thus chaperone a process 
of immunologic reeducation 
(Figure 6) that alters the host's 
immune surveillance as well as 
the migrating cells' reactivity. 
The precise nature of that 
reeducation remains uncertain. 
In a suppressor mechanism, 
donor cells would be bystanders 
disrupting intercellular signal-
ing among recipient cells such 
as CD4 helper T cells and CDB 
cytotoxic T cells. The effect might 
be reverSible, with resumption 
of clonal cytotoxiC T-cell prolifer-
ation if the suppressor cells fail 
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Figure 5. The donor cell type crucial for induction of host 
tolerance to a graft appears to be the dendritic leuko-
cyte, now known to be culturable in medium enriched in 
granulocyte-macrophage colony-stimulating factor. The 
dendritic leukocytes shown were isolated after nine 
days of culture of nonparenchymal cells extracted from 
murine liver. Transmission (left) and scanning (right) 
electron micrographs demonstrate dendritic-cell mor-
phology, including an irregular nucleus, prominent nu-
cleoli, and veil-like extensions of the cell surface. In fur-
ther studies, the cells have shown functional attributes 
of dendritic cells, including phagocytic activity, an ability 
to home in on a host's lymph nodes and spleen, and a 
strong influence on host T cells by antigen presentation. 
to block activation signals. In a 
veto mechanism, the antigen-
presenting donor cell would it-
self be a "veto cell," irreversibly 
inactivating certain class I reac-
tive cytotoxic T cells-namely, 
those host cells capable of recog-
nizing and destroying donor 
cells. The work of Judith 
Thomas and colleagues at East 
Carolina University and now the 
University of Alabama impli-
cates CD8 dendritic cells as can-
didate veto cells subserving 
tolerogenesis in a monkey model 
of combined kidney and bone 
marrow transplantation. Con-
sidering the present state of 
knowledge, however, it might be 
best not to ascribe tolerogenesis 
to any single mechanism. In im-
mune reactions, nature appears 
to favor redundancy, with its op-
portunities for multiple levels of 
control. 
Somewhat less uncertain is 
how the chimerism following 
organ transplantation might 
perpetuate itself for months in 
mouse models, and for decades 
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in human transplant reCipients, 
when the lifespan of the dendrit-
ic cell is thought to be only days 
or weeks. The identification of 
donor dendritic-cell precursors 
in the bone marrow of mouse 
liver allograft reCipients up to 
a half-year after the surgery 
(equivalent to many years of 
human life) implies that the host 
bone marrow and the engrafted 
organ may both become reposi-
tories of dendritic-cell precur-
sors. The precursors might in-
clude both pluripotent stem 
cells and their progeny of imma-
ture but committed cells. Donor 
cells could not be found in the 
bone marrow of mice that had 
acutely rejected a cardiac allo-
graft. 
Therapeutic Implications 
Awareness that chimerism is 
a prerequisite for graft accep-
tance suggests strategies for 
moving toward the goal of drug-
free graft acceptance. For one, 
there may be a perioperative 
window for adjuvant infUSion 
of unaltered HLA-incompatible 
bone marrow or donor-specific 
blood cells (or perhaps eventual-
ly dendritic-cell precursors cul-
tured from the donor). A clinical 
trial under way in Pittsburgh in-
cludes more than 100 reCipients 
of cadaveric organs (kidney, 
liver, heart, lung, or small bowel) 
who also received, without 
alteration of their standard im-
munosuppressive regimen of 
tacrolimus and prednisone, an 
infusion of 3 to 5 X 108 cells/kg 
from the bone marrow of the 
cadaver's thoracicolumbar ver-
tebrae, a rich source of leuko-
cytes that tends to show a rela-
tively low proportion of mature 
T cells. 
At four to 16 months, the first 
18 patients have had a good clin-
ical outcome, and all but one 
(who could not be studied owing 
to perfect HLA matching with a 
donor of the same sex) have 
shown blood chimerism exceed-
ing by more than a thousandfold 
the chimerism typical after organ 
Figure 6. Ability of donor antigen-presenting cells 
(APes) to "reeducate" the immune system of a trans-
plant recipient may take multiple forms. After transplan-
tation, donor APes (notably, dendritic cells) migrate 
from the graft into the recipient (top left), activating rest-
ing helper T cells (Th). These in turn participate'in the 
generation of cytotoxic T lymphocytes (eTls) specific 
for the graft. This cascade, however, can be altered, pre-
sumably by donor dendritic cells at various stages of ac-
tivation. Donor cells acting by a suppressor mechanism 
would reversibly block a host-cell interaction (exempli-
fied here by blockade of cytokine activation signals from 
a Th cell to a resting pre-eTl). In a veto mechanism, 
donor cells would specifically and irreversibly disable 
host eTLs capable of recognizing the donor phenotype. 
There is also evidence that emigrating donor dendritic 
cells (bottom left), because of their immature phenotype, 
may anergize rather than activate resting Th cells. All 
these interactions could induce donor-specific hypo-
responsiveness, leading to allograft acceptance. 
transplantation alone. Rejection 
has been controlled with no un-
usual difficulty. The group's high 
rate of survival marks them as 
the first to undergo HLA-mis-
matched cadaveric organ trans-
plantation with reasonable ex-
pectation that some may become 
drug-free after five to 10 years. 
Perioperative infusions of 
donor lymphoreticular cells 
may be most notably useful in 
improving outcomes for trans-
plantation of organs other than 
the liver. If the inherent capacity 
of an engrafted organ to promote 
its own acceptance depends on 
its content of immunologically 
active cells, the liver stands up-
permost in tolerogenicity, with 
lung less inherently tolerogenic, 
and the heart and kidney least 
so. A micro chimeric state in-
duced by engraftment of HLA-
mismatched bone marrow (and 
institution of immunosuppres-
sion) in the absence of any organ 
transplantation may also prove 
valuable for its own sake. The in-
triguing findings of metabolic 
correction following liver trans-
plantation for type IV glycogen 
storage disease or type I Gauch-
er's disease indicate that amelio-
ration of these and other pancel-
lular enzyme deficiencies may 
not require total marrow re-
placement. 
Eventually, adjuvant infusion 
of donor immune cells may ben-
efit whole-organ xenotransplan-
tation. In laboratory models of 
such efforts involving engraft-
ments from hamster to rat. the 
first immunologic hurdle is 
raised by pre-formed xenospe-
cific antibodies. which rapidly 
damage the graft's blood vessels. 
If that crisis can be averted, bi-
directional cell migrations have 
already been found to establish 
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the same mutual chimerism that 
occurs in allotransplantation. 
The chief causes of late death 
in current long-term studies of 
human organ-transplant recipi-
ents are complications of immu-
nosuppression. Between June 
1992 and June 1995, a prospec-
tive trial of weaning from such 
treatment has enrolled 73 liver 
recipients. Complete weaning 
has been accomplished in 20 
(27%), with as much as 35 
months offollow-up, and is pro-
gressing in 31 (42%), many of 
whom have been taking only 
homeopathiC doses for as long 
as 33 months. Immunosuppres-
sion has been resumed in 22 pa-
tients (30%). In only two in-
stances has histologically severe 
rejection occurred. It resolved 
after reinstitution of immuno-
suppression, without graft loss 
or demonstrable loss of graft 
function. 
For kidney recipients, wean-
ing appears to be more perilous. 
Even so, it seems feasible in iso-
lated cases. Of 10 survivors of 
kidney transplantations per-
formed in 1962 and 1963, five 
have been drug-free for one to 
30 years. Long-term monitoring 
of a transplant recipient's evolv-
ing donor-specific nonreactivity 
may eventually aSSist in deciSion 
making regarding continued im-
munosuppression. 
Conclusion 
The mutual chimerism arising 
after successful organ trans-
plantation can be viewed as 
cancelling the immunologic ef-
fects of donor and reCipient. 
Throughout the process, howev-
er, the abundance of donor im-
mune cells remains small com-
pared with the numbers of host 
leukocytes. As managed by cur-
rent immunosuppressive regi-
mens, the process proceeds 
slowly in even the most success-
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ful cases. Failure manifests itself 
as graft rejection, graft-versus-
host disease ("host rejection"), 
or sometimes both. Iatrogenical-
ly disabling the reCipient side at 
the outset, as is done in bone 
marrow transplantation, ren-
ders the host prone to graft-ver-
sus-host disease and necessi-
tates HLA matching. Leaving 
both sides intact, as in organ 
transplantation, removes the ne-
cessity for HLA matching and di-
minishes the risk of graft-ver-
sus-host disease, 
Thus the apparent gap be-
tween bone marrow and solid 
organ transplantation is sinlply 
the outcome of entrenched dif-
ferences in treatment strategies. 
On closer inspection, the gap es-
sentially disappears. In receiv-
ing an organ transplant, patients 
also receive "passenger leuko-
cytes"-a covert bone marrow 
transplant. On the other hand, it 
seems highly unlikely that cy-
toablative pretreatment of bone-
marrow reCipients ever com-
pletely destroys the host im-
mune system. Even in patients 
with the best outcomes, sensi-
tive techniques have now re-
vealed trace populations of sur-
viving host leukocytes. Such pa-
tients are in fact mirror images 
of solid-organ reCipients (in 
whom donor immune cells are 
the numerical minority), In ei-
ther group, the seminal event in 
successful engraftment appears 
to be chimerization. D 
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